OPKO HEALTH amends GeneDx Holdings stake filing
Ticker: OPK · Form: SC 13D/A · Filed: Nov 20, 2024 · CIK: 944809
| Field | Detail |
|---|---|
| Company | Opko Health, INC. (OPK) |
| Form Type | SC 13D/A |
| Filed Date | Nov 20, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $68.20, $82.00, $28,254,209, $61,105,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, ownership-change, amendment
TL;DR
OPKO HEALTH filed an update on their GeneDx Holdings stake. Check the details.
AI Summary
OPKO HEALTH, INC. filed an amendment to its Schedule 13D on November 20, 2024, regarding its beneficial ownership of GeneDx Holdings Corp. The filing indicates a change in the reporting person's holdings, though specific new dollar amounts or percentages are not detailed in this excerpt. This amendment is a routine update to their previous filings concerning GeneDx.
Why It Matters
This filing provides updated information on significant ownership changes for GeneDx Holdings Corp., which could influence its stock performance and strategic direction.
Risk Assessment
Risk Level: medium — Amendments to Schedule 13D filings can signal shifts in major shareholder intentions, potentially impacting stock price.
Key Players & Entities
- OPKO HEALTH, INC. (company) — Reporting Person
- GeneDx Holdings Corp. (company) — Subject Company
- Sema4 Holdings Corp. (company) — Former Name of GeneDx Holdings Corp.
- CM Life Sciences, Inc. (company) — Former Name of GeneDx Holdings Corp.
- Opko Health, Inc. (company) — Former Name of OPKO HEALTH, INC.
- eXegenics Inc (company) — Former Name of OPKO HEALTH, INC.
FAQ
What is the specific change in OPKO HEALTH, INC.'s beneficial ownership of GeneDx Holdings Corp. reported in this amendment?
The provided excerpt does not specify the exact percentage or number of shares that changed hands, only that an amendment to the Schedule 13D was filed on November 20, 2024, indicating a change in reporting person's holdings.
When was the previous name of GeneDx Holdings Corp. changed?
GeneDx Holdings Corp. was formerly known as Sema4 Holdings Corp. after a name change on July 21, 2021, and prior to that, CM Life Sciences, Inc. after a name change on July 15, 2020.
What is the business address of GeneDx Holdings Corp.?
The business address for GeneDx Holdings Corp. is 333 Ludlow Street, North Tower, 8th Floor, Stamford, CT 06902.
What is the business address of OPKO HEALTH, INC.?
The business address for OPKO HEALTH, INC. is 4400 Biscayne Blvd., Miami, FL 33137.
What is the SEC Act under which this filing was made?
This filing was made under the Securities Exchange Act of 1934.
Filing Stats: 1,222 words · 5 min read · ~4 pages · Grade level 8.3 · Accepted 2024-11-20 21:36:13
Key Financial Figures
- $0.0001 — suer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securiti
- $68.20 — the open market at prices ranging from $68.20 to $82.00 per share for an aggregate sa
- $82.00 — market at prices ranging from $68.20 to $82.00 per share for an aggregate sale price o
- $28,254,209 — n aggregate sale price of approximately $28,254,209. ITEM 5. Interest in Securities of
- $61,105,000 — n aggregate sale price of approximately $61,105,000. Sales of GeneDx Common Stock prior to
Filing Documents
- opk20241118_sc13da.htm (SC 13D/A) — 63KB
- 0001437749-24-035895.txt ( ) — 65KB
is amended by adding the following paragraph to the end of the item
Item 4 is amended by adding the following paragraph to the end of the item: In a series of transactions between November 11, 2024 and November 20, 2024, OPKO sold a total of 375,833 shares of GeneDx Common Stock on the open market at prices ranging from $68.20 to $82.00 per share for an aggregate sale price of approximately $28,254,209. ITEM 5. Interest in Securities of the Issuer.
is deleted in its entirety and replaced with the following text
Item 5 is deleted in its entirety and replaced with the following text: (a) The Company's beneficial ownership of GeneDx Common Stock is as set forth in the table below: Name and Title of Beneficial Owner Number of Outstanding Shares Beneficially Owned Percentage of Outstanding Common Shares (1) OPKO Health, Inc. 1,370,841 4.99% ______________ (1) Based on 27,471,397shares of GeneDx Common Stock of the Issuer outstanding on October 22, 2024, as set forth in the Issuer's Form 10-Q filed with the SEC on October 29, 2024. (b) Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5. (c) In the last 60 days prior to the filing of this Amendment No. 9, OPKO sold a total of 800,833 shares of GeneDx Common Stock on the open market at prices ranging from $68.20 to $82.00 per share for an aggregate sale price of approximately $61,105,000. Sales of GeneDx Common Stock prior to November 11, 2024 were previously reported in Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7, and Amendment No.8. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days. Date Shares of Common Stock Aggregate Sale Price Weighted Price Per Share 11/4/24 25,000 $ 1,902,415 $ 76.0966 11/5/24 75,000 $ 5,699,171 $ 75,9889 11/6/24 150,000 $ 11,510,776 $ 76.7385 11/7/24 50,000 $ 3,861,068 $ 77.2214 11/8/24 125,000 * $ 9,877,361 $ 79.0189 11/11/24 100,000 $ 7,576,946 $ 75.7695 11/13/24 125,000 $ 10,020,291 $ 80.1623 11/18/24 50,000 $ 3,586,620 $ 71.7324 11/19/24 40,833 $ 2,913,787 $ 71.3586 11/20/24 60,000 $ 4,156,566 $ 69.2761 CUSIP No. 81663L200 Schedule 13D PAGE 4 of 5 * Amendment No.8 erroneously reported 10,000 shares sold on November 8, 2024, which resulted in the incorrect aggregate number of shares reported purcha
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. OPKO Health, Inc. Dated: November 20, 2024 By: /s/ Steven D. Rubin Name: Steven D. Rubin Title: Executive Vice President - Administration